Buckingham Strategic Wealth’s Galectin Therapeutics GALT Stock Holding History

Buckingham Strategic Wealth’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$29.9K	Hold	13,234	–	–	﹤0.01%	757
2024 Q1	$31.6K	Hold	13,234	–	–	﹤0.01%	752
2023 Q4	$22K	Hold	13,234	–	–	﹤0.01%	720
2023 Q3	$25.4K	Hold	13,234	–	–	﹤0.01%	682
2023 Q2	$19.1K	Hold	13,234	–	–	﹤0.01%	693
2023 Q1	$15K	Hold	13,234	–	–	﹤0.01%	615
2022 Q4	$15K	Hold	13,234	–	–	﹤0.01%	617
2022 Q3	$22K	Hold	13,234	–	–	﹤0.01%	598
2022 Q2	$17K	Hold	13,234	–	–	﹤0.01%	601
2022 Q1	$21K	Hold	13,234	–	–	﹤0.01%	594
2021 Q4	$27K	Buy	13,234 +2,500	+23%	+$7.14K	﹤0.01%	594
2021 Q3	$42K	Buy	+10,734	New	+$36.4K	﹤0.01%	586
2019 Q2	–	Sell	-10,000	Closed	-$51K	–	447
2019 Q1	$51K	Hold	10,000	–	–	0.01%	414
2018 Q4	$34K	Hold	10,000	–	–	0.01%	342
2018 Q3	$60K	Hold	10,000	–	–	0.01%	356
2018 Q2	$64K	Hold	10,000	–	–	0.01%	353
2018 Q1	$47K	Hold	10,000	–	–	0.01%	309
2017 Q4	$33K	Sell	10,000 -40,000	-80%	-$101K	0.01%	316
2017 Q3	$107K	Hold	50,000	–	–	0.03%	281
2017 Q2	$123K	Hold	50,000	–	–	0.03%	289
2017 Q1	$115K	Buy	+50,000	New	+$75.4K	0.03%	251

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Buckingham Strategic Wealth's GALT Position: Q2 2024 in Review

Buckingham Strategic Wealth held its Galectin Therapeutics (GALT) position steady in Q2 2024 at 13,234 shares worth $29.9K. The position accounts for ﹤0.01% of the portfolio, ranked #757.

Buckingham Strategic Wealth first reported a position in GALT in Q1 2017 and has held it in 21 quarters since. The position peaked at $123K in Q2 2017. 73 funds tracked by Wall St. Rank hold GALT as of Q2 2024.

Buckingham Strategic Wealth held 13,234 shares of Galectin Therapeutics worth $29.9K as of Q2 2024.
Buckingham Strategic Wealth left its Galectin Therapeutics share count unchanged in Q2 2024.
Galectin Therapeutics made up ﹤0.01% of Buckingham Strategic Wealth's portfolio in Q2 2024, its #757 holding.
Buckingham Strategic Wealth first reported a position in Galectin Therapeutics in Q1 2017 and has held it in 21 quarters since.
Buckingham Strategic Wealth's Galectin Therapeutics position peaked at $123K in Q2 2017.
73 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2024.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2024, filed 12 Aug 2024.